Supply Chain Intelligence

SCYNEXIS, Inc. Supply Chain

SCYX supply chain intelligence for SCYNEXIS, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

SCYX ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

2Suppliers
4Customers
3Debt Items
20Related Chains

SCYNEXIS, Inc. Suppliers

TickerNameConfidenceEvidence
MRK Merck & Co., Inc. 72% recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. Our clinical stage compound, SCY-247, is not affected by the…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from SCYX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from SCYX graph: recall affect our ongoing Phase 3 MAR…

SCYNEXIS, Inc. Customers

TickerNameConfidenceEvidence
GSK GSK plc 90% Revenue consists of license agreement revenue associated with the GSK license agreement. | Qwen verified: Explicit mention of GSK license agreement revenue indicates GSK is customer receiving licensi…
GSK GSK plc 90% Reciprocal relationship from GSK graph: Reciprocal relationship from SCYX graph: Reciprocal relationship from GSK graph: Reciprocal relationship from SCYX graph: Reciprocal relationship from GSK grap…
MRK Merck & Co., Inc. 72% recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. Our clinical stage compound, SCY-247, is not affected by the…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from SCYX graph: recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERG…

SCYNEXIS, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SCYX-DEBT Debt stack $2.1M 90% Market cache reports total debt of $2.1M.
SCYX-DEBT-12431 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
SCYX-DEBT-12430 Warrants outstanding: 1319807 90% xbrl warrant detail from xbrl 2025-12-31.

SCYNEXIS, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for SCYNEXIS, Inc..

SCYNEXIS, Inc. Ownership

HolderNameConfidenceEvidence
SCYX-OWNER-SQUADRON-CAPITAL-MANAGEMENT-LLC Squadron Capital Management LLC 90% 13F overlay lists Squadron Capital Management LLC as top holder; 45 tracked holders.

SCYNEXIS, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DEO Diageo plc 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
SMMT Summit Therapeutics Inc. 100.00 2
MRK Merck & Co., Inc. 100.00 1 ['customer', 'supplier']
BDRX Biodexa Pharmaceuticals Plc 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
LEGN Legend Biotech Corporation 100.00 2
PCVX Vaxcyte, Inc. 100.00 2
LIXT Lixte Biotechnology Holdings, Inc. 100.00 2
GSK GSK plc 60.75 1 ['customer']
BNBX BNB Plus Corp. 50.00 2
EDSA Edesa Biotech, Inc. 50.00 2
DYN Dyne Therapeutics, Inc. 50.00 2
DKS DICK'S Sporting Goods, Inc. 50.00 2
PSNL Personalis, Inc. 50.00 2
CTMX CytomX Therapeutics, Inc. 50.00 2
CBIH Cannabis Bioscience International Holdings, Inc. 50.00 2
EVFM Evofem Biosciences, Inc. 50.00 2
CYTK Cytokinetics, Incorporated 50.00 2
SDGR Schrödinger, Inc. 50.00 2
View SCYX supply chain intel →

Explore the full interactive supply chain map for SCYNEXIS, Inc..

Open SCYX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map